Ontinua ER FDA Approval Status
Ontinua ER (arbaclofen) is a prodrug of R-baclofen in devleopment for the treatment of spasticity associated with multiple sclerosis.
Development Timeline for Ontinua ER
|Sep 28, 2015||Osmotica Announces FDA Acceptance of Filing for Ontinua ER for Alleviation of Spasticity Resulting from Multiple Sclerosis|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.